Clinical trials: Scalp Psoriasis
Scalp Psoriasis
Comparison Of Efficacy Of Tazarotene 0.045% Vs Halobetasol Propionate 0.01% Lotion For Treatment of Scalp Psoriasis
Psoriasis is a serious, immune-driven illness that affects around 2% of the population and has a wide range of clinical manifestations 1-3 .
- Trial name
- NCT06015152
- Testing
- Tazarotene 0.045% Topical Application Lotion [ARAZLO]
- Where
- Pakistan
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Jinnah Postgraduate Medical Centre
Scalp Psoriasis
Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis
A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site, Phase III Clinical Study to Evaluate the Efficacy and Safety of DSXS topical product in Patients with Mild to Severe Scalp Psoriasis
- Trial name
- NCT02933866
- Testing
- DSXS topical, Vehicle topical
- Where
- United States
- Volunteers
- 371 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Psoriasis
Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment with DSXS .
- Trial name
- NCT02933528
- Testing
- DSXS Topical product
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Psoriasis of Scalp
Immune Spatial Features of Guselkumab Cutaneous Response
This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.
- Trial name
- NCT05858632
- Testing
- Guselkumab
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Seborrheic Dermatitis, Psoriasis of Scalp
Study to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of Scalp
Observational, descriptive, retrospective, multicenter study to evaluate the safety of the treatment with Sebryl® and / or Sebryl Plus® in the management of seborrheic dermatitis and psoriasis of the scalp in routine medical…
- Trial name
- NCT05105139
- Testing
- Allantoin/ Coal Tar/ Clioquinol, Allantoin/ Coal Tar/ Clioquinol/ Triclosan
- Where
- Mexico
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Scalp Psoriasis
Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product
An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use DSXS topical product (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Moderate to SevereScalp Psoriasis
- Trial name
- NCT02933502
- Testing
- DSXS topical product
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Scalp Psoriasis, Pustular Palmo-plantar Psoriasis
IL-17 Role in Variants of Psoriasis
The goal of this project is to study some mechanisms involved in the dysregulation of the immune system observed in the skin of subjects with psoriasis.
- Conditions
- Scalp Psoriasis, Pustular Palmo-plantar Psoriasis, Non-pustular Palmo-plantar Psoriasis, Elbow Psoriasis
- Trial name
- NCT02078297
- Where
- Canada
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Innovaderm Research Inc.
Plaque Psoriasis
Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris
This is an open label, investigator-blinded, cross over, prospective, single center study of subjects with plaque psoriasis. Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment and Taclonex Scalp®…
- Trial name
- PSTaclonex (NCT01707043)
- Testing
- Taclonex
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Wake Forest University
Scalp Psoriasis
A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis
The objectives of this research are to demonstrate the following:1. To demonstrate improvement in hair growth and hair appearance following 12 weeks of once daily treatment with tazarotene/halobetasol lotion in patients with…
- Trial name
- NCT05872256
- Testing
- 0.045% Tazarotene/0.01% Halobetasol Lotion
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Dermatology Consulting Services, PLLC